Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Core Insights - Arvinas, Inc. is set to review its third-quarter 2025 financial results and provide a corporate update on November 5, 2025 [1] - The company specializes in targeted protein degradation therapies through its PROTAC platform, aiming to treat various debilitating diseases [3] Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies for life-threatening diseases [3] - The company utilizes its PROTAC (PROteolysis TArgeting Chimera) platform to create drugs that selectively degrade disease-causing proteins [3] - Current investigational drugs include ARV-102 for neurodegenerative disorders, ARV-393 for non-Hodgkin Lymphoma, ARV-806 for mutated cancers, and vepdegestrant for ER+/HER2- breast cancer [3]